GenSight Biologics S.A.
EPA:SIGHT.PA
0.315 (EUR) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.267 | 2.582 | 5.276 | 4.394 | 0.7 | 4.346 | 3.702 | 3.001 | 3.56 | 1.103 | 0.908 |
| Cost of Revenue
| -1.733 | 0 | 0 | 0 | 0 | 0.315 | 0.224 | 0.203 | 0.139 | 0 | 0 |
| Gross Profit
| 3 | 2.582 | 5.276 | 4.394 | 0.7 | 4.031 | 3.478 | 2.798 | 3.421 | 1.103 | 0.908 |
| Gross Profit Ratio
| 2.368 | 1 | 1 | 1 | 1 | 0.928 | 0.939 | 0.932 | 0.961 | 1 | 1 |
| Reseach & Development Expenses
| 16.603 | 18.938 | 22.554 | 21.989 | 28.156 | 29.031 | 18.675 | 18.529 | 10.722 | 6.197 | 2.786 |
| General & Administrative Expenses
| 6.499 | 8.006 | 5.68 | 2.981 | 2.751 | 4.501 | 3.054 | 1.709 | 4.203 | 0.696 | 0.425 |
| Selling & Marketing Expenses
| 0.768 | 0.231 | 0.214 | 0.227 | 0.044 | 0.16 | 0.034 | 0 | 0 | 0 | 0 |
| SG&A
| 13.022 | 8.237 | 5.894 | 3.208 | 2.795 | 4.661 | 3.088 | 1.709 | 4.203 | 0.696 | 0.425 |
| Other Expenses
| 4.336 | 3.242 | 4.953 | 4.131 | 0.047 | -0.647 | 2.226 | 1.781 | -1.264 | -0.15 | -0.372 |
| Operating Expenses
| 29.625 | 30.417 | 33.401 | 29.328 | 30.998 | 33.045 | 23.989 | 22.019 | 13.661 | 6.743 | 2.838 |
| Operating Income
| -31.392 | -27.835 | -28.126 | -24.934 | -30.298 | -33.045 | -23.99 | -22.019 | -13.661 | -6.743 | -2.838 |
| Operating Income Ratio
| -24.777 | -10.78 | -5.331 | -5.675 | -43.283 | -7.604 | -6.48 | -7.337 | -3.837 | -6.115 | -3.124 |
| Total Other Income Expenses Net
| 3.475 | 0.216 | -0.489 | -9.08 | -0.408 | -0.408 | -0.12 | -0.063 | 0.008 | 0.072 | 0.076 |
| Income Before Tax
| -27.917 | -27.619 | -28.615 | -34.014 | -30.706 | -33.453 | -24.11 | -22.082 | -13.654 | -6.671 | -2.763 |
| Income Before Tax Ratio
| -22.034 | -10.697 | -5.424 | -7.741 | -43.866 | -7.697 | -6.513 | -7.358 | -3.835 | -6.05 | -3.041 |
| Income Tax Expense
| -1.697 | 0.005 | 0.002 | 0.002 | 0.004 | 0.408 | 0.002 | 0.063 | -0.049 | -0.165 | -0.151 |
| Net Income
| -26.22 | -27.624 | -28.617 | -34.016 | -30.71 | -33.453 | -24.112 | -22.082 | -13.654 | -6.671 | -2.763 |
| Net Income Ratio
| -20.695 | -10.699 | -5.424 | -7.741 | -43.871 | -7.697 | -6.513 | -7.358 | -3.835 | -6.05 | -3.041 |
| EPS
| -0.54 | -0.6 | -0.63 | -0.97 | -1.08 | -1.37 | -1.1 | -1.36 | -1.21 | -0.75 | -0.32 |
| EPS Diluted
| -0.54 | -0.6 | -0.63 | -0.97 | -1.08 | -1.37 | -1.1 | -1.36 | -1.21 | -0.75 | -0.32 |
| EBITDA
| -28.358 | -26.444 | -26.83 | -24.012 | -29.333 | -32.73 | -23.81 | -21.789 | -13.564 | -6.581 | -2.874 |
| EBITDA Ratio
| -22.382 | -10.242 | -5.085 | -5.465 | -41.904 | -7.531 | -6.432 | -7.261 | -3.81 | -5.968 | -3.164 |